Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Files An 8-K Other EventsItem 8.01. Other Events
On December 14, 2016, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release announcing that the Company received a letter from Fundação Oswaldo Cruz (Fiocruz), an arm of the Brazilian Ministry of Health (the “Brazilian Ministry”), detailing intended purchases by the Brazilian Ministry of alfataliglicerase to treat Gaucher patients in Brazil. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
99.1 Press release dated December 14, 2016.
About Protalix BioTherapeutics, Inc. (NYSEMKT:PLX)
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system (ProCellEx). The Company has developed taliglucerase alfa (marketed under the name Uplyso in Brazil and certain other Latin American countries and Elelyso in the rest of the territories) for the treatment of Gaucher disease that is approved for marketing in the United States, Brazil, Israel and other markets. The Company developed Elelyso using ProCellEx system and is focused on utilizing the system to develop a pipeline of clinically superior versions of recombinant therapeutic proteins that primarily target pharmaceutical markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company’s product pipeline includes PRX-102, PRX-106, PRX-112 and PRX-110. Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Recent Trading Information
Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) closed its last trading session up +0.045 at 0.345 with 13,666,630 shares trading hands.